The release of the 750mcg teriparatide formulation in Australia has seen controlled distribution to date. Primarily designated for patients with severe bone loss who have not responded to other medications, access is selectively managed. Current supply quantities are tight , and individuals should confirm from their doctor the recent information… Read More